A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

Phase 1 Terminated 40 enrolled Pfizer

Open-labelTreatment

Summary

To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Timeline

Start: 2014-06
Primary completion: 2017-07
Completion: 2017-07

Outcome

Outcome not reported

Stopped: “The study was terminated due to a change in sponsor prioritization.”

Publications

Rosen LS, Wesolowski R, Baffa R, Liao KH, Hua SY, Gibson BL, Pirie-Shepherd S, Tolcher AW. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest New Drugs. 2020 Feb;38(1):120-130. doi: 10.1007/s10637-019-00754-y. Epub 2019 Mar 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-06650808	Other / unclassified	0.2 mg/kg	Intravenous
Subject	PF-06650808	Other / unclassified	2 mg/kg	Intravenous
Subject	PF-06650808	Other / unclassified	2.4 mg/kg	Intravenous
Subject	PF-06650808	Other / unclassified	6.4 mg/kg	Intravenous